BRIEF-FDA to inspect Nicox partner Bausch + Lomb

Fri Jul 22, 2016 3:19am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 22 (Reuters) - Nicox SA :

* Has been informed by its partner Bausch + Lomb, a Valeant unit, of receipt of a complete response letter from U.S. FDA concerning latanoprostene bunod

* FDA's letter did not identify any efficacy or safety concerns with respect to NDA or additional clinical trials needed for approval of NDA for latanoprostene bunod ophthalmic solution, 0.024 pct

* Concerns raised by the FDA pertain to a Current Good Manufacturing Practice (CGMP) inspection at Bausch + Lomb's manufacturing facility in Tampa, Florida

* Some deficiencies were identified by the FDA at the Tampa plant

* Valeant intends to meet with FDA as soon as possible to work on a resolution and address these concerns Source text for Eikon: Further company coverage: (Gdynia Newsroom)